Kymera Therapeutics (KYMR) Net Margin (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Net Margin of 201.47% for Q1 2026, up 9528.0% year-over-year from 2.09% in Q1 2025, and up 93.35% quarter-over-quarter from 3030.7% in Q4 2025.
Powered by 
Analysis
Kymera Therapeutics (KYMR) Net Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Net Margin for 8 consecutive years, with 201.47% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 9528.0% year-over-year to 201.47%; the TTM figure through Mar 2026 stood at 611.96% (down 20288.0% YoY), while the FY2025 annual figure was 794.04%, down 31847.0% from the prior year.
- Net Margin advanced to 201.47% in Q1 2026 per KYMR's latest filing, from 3030.7% in the prior quarter.
- Across five years, Net Margin topped out at 30.01% in Q4 2023 and bottomed at 3030.7% in Q4 2025.
- Historically, Net Margin has averaged 883.25% across 5 years, with a median of 450.24% in 2022.
- Annual changes were most pronounced in 2023 — Net Margin jumped 131868 bps — and 2025, when it slumped 207381 bps.
- Kymera Therapeutics' Net Margin stood at 216.03% in 2022, then surged by 86 bps to 30.01% in 2023, then slumped by 3089 bps to 956.88% in 2024, then tumbled by 217 bps to 3030.7% in 2025, then soared by 93 bps to 201.47% in 2026.
- Business Quant data shows KYMR's Net Margin at 201.47% in Q1 2026, 3030.7% in Q4 2025, and 2973.05% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Kymera Therapeutics | 11.52 Bn | 10.83 Bn | - | -94.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -94.17% |
| Mar 31, 2026 | -201.47% |
| Dec 31, 2025 | -3,030.70% |
| Sep 30, 2025 | -2,973.05% |
| Jun 30, 2025 | -667.60% |
| Mar 31, 2025 | -296.75% |
| Dec 31, 2024 | -956.88% |
| Sep 30, 2024 | -1,670.33% |
| Jun 30, 2024 | -163.98% |
| Mar 31, 2024 | -472.02% |
| Dec 31, 2023 | -30.01% |
| Sep 30, 2023 | -1,118.17% |
| Jun 30, 2023 | -234.96% |
| Mar 31, 2023 | -432.37% |
| Dec 31, 2022 | -216.03% |
| Sep 30, 2022 | -450.24% |
| Jun 30, 2022 | -349.64% |
| Mar 31, 2022 | -384.27% |
| Dec 31, 2021 | -222.88% |
| Sep 30, 2021 | -141.16% |